Products & Services · Revenue

Collaboration and Other Revenue — Revenue

Eli Lilly Collaboration and Other Revenue — Revenue increased by 35.7% to $1.35B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.4%, from $1.13B to $1.35B. Over 4 years (FY 2021 to FY 2025), Collaboration and Other Revenue — Revenue shows an upward trend with a 15.6% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2016
Last reportedQ1 2026Apr 30, 2026
Rolls up toTotal Revenue

How to read this metric

An increase suggests successful monetization of intellectual property or expanded partnership activity, while a decrease may indicate fewer active collaborations or expiring licensing agreements.

Detailed definition

This metric represents revenue generated through strategic partnerships, licensing agreements, and other non-core produc...

Peer comparison

Peers in the pharmaceutical industry often report this under 'Other Revenue' or 'Licensing and Collaboration Revenue,' which varies significantly based on the company's reliance on external R&D partnerships.

Metric ID: lly_segment_collaborationand_other_revenue_revenues

Historical Data

20 periods
 Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$669.60M$583.80M$621.50M$677.10M$617.10M$822.40M$962.00M$721.80M$1.33B$2.19B$1.06B$971.50M$947.90M$867.50M$1.51B$1.13B$831.70M$1.27B$991.70M$1.35B
QoQ Change-12.8%+6.5%+8.9%-8.9%+33.3%+17.0%-25.0%+84.6%+64.6%-51.5%-8.7%-2.4%-8.5%+73.8%-25.3%-26.2%+52.7%-21.9%+35.7%
YoY Change-7.8%+40.9%+54.8%+6.6%+115.9%+166.6%+10.6%+34.6%-28.9%-60.4%+41.8%+16.0%-12.3%+46.4%-34.2%+19.4%
Range$583.80M$2.19B
CAGR+15.8%
Avg YoY Growth+25.6%
Median YoY Growth+17.7%

Frequently Asked Questions

What is Eli Lilly's collaboration and other revenue — revenue?
Eli Lilly (LLY) reported collaboration and other revenue — revenue of $1.35B in Q1 2026.
How has Eli Lilly's collaboration and other revenue — revenue changed year-over-year?
Eli Lilly's collaboration and other revenue — revenue increased by 19.4% year-over-year, from $1.13B to $1.35B.
What is the long-term trend for Eli Lilly's collaboration and other revenue — revenue?
Over 4 years (2021 to 2025), Eli Lilly's collaboration and other revenue — revenue has grown at a 15.6% compound annual growth rate (CAGR), from $2.36B to $4.22B.
What does collaboration and other revenue — revenue mean?
Revenue earned from strategic partnerships, licensing deals, and royalty agreements rather than direct product sales.